%0 Journal Article
%T Paradigm Shift of Healthcare Cost for Patients with Inflammatory Bowel Diseases: A Claims Data-Based Analysis in Japan
%A Kenji Suzuki
%A Kouhei Akazawa
%A Kyoko Nakazawa
%A Shota Saito
%A Takashi Ishikawa
%J -
%D 2019
%R https://doi.org/10.3390/gidisord1010009
%X Abstract Anti-tumor necrosis factor-¦Á (anti-TNF¦Á) agents are used for induction and maintenance of remission in patients with inflammatory bowel diseases (IBD). However, biologic drugs present a large economic burden on health insurance systems. We aimed to estimate the mean annual health care cost per patient with IBD and cost contribution of anti-TNF¦Á agents. We performed an analysis of patients with Crohn¡¯s disease (CD) and ulcerative colitis (UC) based on a large-scale administrative claims database constructed by Japan Medical Data Center (JMDC) Co. Ltd., comprising inpatient, outpatient, and pharmacy claims data. We evaluated all claims from 1 April 2013 through 31 March 2016. Descriptive statistics were used to measure median health care costs paid per member per year (PMPY) and the relative cost contribution of anti-TNF¦Á agents. A total 1405 patients with CD and 5771 with UC were included. Median costs PMPY were approximately six times higher for CD than UC (JPY 1,957,320 and JPY 278,760, respectively). Medication cost for anti-TNF¦Á agents was the main cost driver, accounting for 59.9% and 17.8% of the total costs for CD and UC, respectively. In Japan, costs for anti-TNF¦Á agents have resulted in drug costs exceeding inpatient costs for IBD. Optimized use of anti-TNF¦Á agents and introduction of biosimilars for anti-TNF¦Á agents can be expected to substantially reduce the health care costs of IBD. View Full-Tex
%K biosimilars
%K claims data
%K health care costs
%K inflammatory bowel diseases
%U https://www.mdpi.com/2624-5647/1/1/9